Statins to Prevent Cancer Associated Blood Clots

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 4000 participants.

Also called NCT07303816

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; triple masking; primary purpose prevention
Phase
Phase 4
Enrolled
  • 4,000 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07303816
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
United States (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07303816. Randomized; triple masking; primary purpose prevention. Start 2026-06-11 (actual); primary completion 2031-03-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Statins to Prevent Cancer Associated Blood Clots
Acronym
STAT-CAT
Condition
Venous Thromboembolism
Condition
Cancer
Condition
Cardiovascular Events
Intervention (Drug)
Rosuvastatin
Intervention (Drug)
Placebo Drug
Lead sponsor
Brigham and Women's Hospital (class: other)
Collaborator
National Heart, Lung, and Blood Institute (NHLBI) (class: US National Institutes of Health)
Collaborator
Dana-Farber/Brigham and Women's Cancer Center (class: other)

Record details

Record id
cardio:ct-nct07303816
Content hash
1a45b5b0716013e06df25de53a3a6b2bbd93435f32500f12d6f7b64682f757df